ProCE Banner Activity

When I Consider Biologic or Targeted Synthetic DMARD Monotherapy for Patients With Rheumatoid Arthritis

Clinical Thought
Here’s my take on the patients who are best suited to receive biologic or targeted synthetic DMARD monotherapy.

Released: June 08, 2018

Expiration: June 07, 2019

No longer available for credit.

Share

Faculty

Roy Fleischmann

Roy Fleischmann, MD

Clinical Professor of Medicine
Department of Medicine
University of Texas Southwestern Medical Center
Co-Director
Metroplex Clinical Research Center
Partner
Rheumatology Associates
Dallas, Texas

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer TEXT Only

Faculty Disclosure

Primary Author

Roy Fleischmann, MD

Clinical Professor of Medicine
Department of Medicine
University of Texas Southwestern Medical Center
Co-Director
Metroplex Clinical Research Center
Partner
Rheumatology Associates
Dallas, Texas

Roy Fleischmann, MD, has disclosed that he has received consulting fees and/or funds for research support from AbbVie, Amgen, Bristol-Myers Squibb, Genentech, Pfizer, Roche, and Sanofi Genzyme.